Flow cytometry biomarkers distinguish DOCK8 deficiency from severe atopic dermatitis
Affiliations
Affiliations
- Division of Immunology, Boston Children's Hospital, Boston, MA, USA.
- Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA, USA.
- Department of Pediatrics, Kuwait University, Kuwait City, Kuwait.
- University Montpellier 2 and CNRS Institute of Human Genetics, Montpellier, France.
- Unit of Medical Genetics, Saint Joseph University, Beirut, Lebanon.
- Department of Pediatrics, University of Kansas Medical Center, Kansas City, KS, USA; Department of Internal Medicine, Division of Genetics, Endocrinology & Metabolism, University of Kansas Medical Center, Kansas City, KS, USA.
- Division of Immunology, Boston Children's Hospital, Boston, MA, USA. Electronic address: raif.geha@childrens.harvard.edu.
Abstract
DOCK8 deficiency is a primary immunodeficiency characterized by recurrent sinopulmonary infections, dermatitis with cutaneous infections, elevated serum IgE levels, eosinophilia, and a high incidence of food allergy. Given the seriousness of DOCK8 deficiency, it is important to recognize it early and initiate appropriate therapy. Diagnosis relies on examining DOCK8 protein expression and sequencing of the 48 exons in the DOCK8 gene, but these assays are not always readily available. A major problem facing clinicians is that DOCK8 deficiency shares many clinical and laboratory features with severe atopic dermatitis. Here, we have identified biomarkers routinely measured by flow cytometry on whole blood in clinical immunology laboratories that may be used in distinguishing DOCK8 deficiency from severe atopic dermatitis. The use of these biomarkers may help the clinician identify those patients who are most likely to have DOCK8 mutations and would benefit from further specialized diagnostic testing.
Keywords: Atopic dermatitis;; B cell; DOCK8;; Hyper-IgE;; T cell;.
Conflict of interest statement
Conflict of Interest Statement
The authors have no conflict of interest.
Similar articles
Current Status of Dedicator of Cytokinesis-Associated Immunodeficiency: DOCK8 and DOCK2.
Dimitrova D, Freeman AF.Dermatol Clin. 2017 Jan;35(1):11-19. doi: 10.1016/j.det.2016.07.002.PMID: 27890234 Free PMC article. Review.
Jacob M, Bin Khalaf D, Alhissi S, Arnout R, Alsaud B, Al-Mousa H, Lopata AL, Alazami AM, Dasouki M, Abdel Rahman AM.Allergy. 2019 Feb;74(2):370-379. doi: 10.1111/all.13610. Epub 2018 Oct 15.PMID: 30252138
Cutaneous manifestations of DOCK8 deficiency syndrome.
Chu EY, Freeman AF, Jing H, Cowen EW, Davis J, Su HC, Holland SM, Turner ML.Arch Dermatol. 2012 Jan;148(1):79-84. doi: 10.1001/archdermatol.2011.262. Epub 2011 Sep 19.PMID: 21931011 Free PMC article.
Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern.
Boos AC, Hagl B, Schlesinger A, Halm BE, Ballenberger N, Pinarci M, Heinz V, Kreilinger D, Spielberger BD, Schimke-Marques LF, Sawalle-Belohradsky J, Belohradsky BH, Przybilla B, Schaub B, Wollenberg A, Renner ED.Allergy. 2014 Jul;69(7):943-53. doi: 10.1111/all.12416.PMID: 24898675
Genetic, clinical, and laboratory markers for DOCK8 immunodeficiency syndrome.
Zhang Q, Davis JC, Dove CG, Su HC.Dis Markers. 2010;29(3-4):131-9. doi: 10.3233/DMA-2010-0737.PMID: 21178272 Free PMC article. Review.
Cited by
Non-additive QTL mapping of lactation traits in 124,000 cattle reveals novel recessive loci.
Reynolds EGM, Lopdell T, Wang Y, Tiplady KM, Harland CS, Johnson TJJ, Neeley C, Carnie K, Sherlock RG, Couldrey C, Davis SR, Harris BL, Spelman RJ, Garrick DJ, Littlejohn MD.Genet Sel Evol. 2022 Jan 24;54(1):5. doi: 10.1186/s12711-021-00694-3.PMID: 35073835 Free PMC article.
Attardi E, Di Cesare S, Amodio D, Giancotta C, Cotugno N, Cifaldi C, Chiriaco M, Palma P, Finocchi A, Di Matteo G, Rossi P, Cancrini C.Front Immunol. 2019 Nov 29;10:2735. doi: 10.3389/fimmu.2019.02735. eCollection 2019.PMID: 31849946 Free PMC article.
Richardson AM, Moyer AM, Hasadsri L, Abraham RS.Curr Allergy Asthma Rep. 2018 Feb 22;18(3):19. doi: 10.1007/s11882-018-0770-1.PMID: 29470720 Review.
DOCK8 deficiency: Insights into pathophysiology, clinical features and management.
Biggs CM, Keles S, Chatila TA.Clin Immunol. 2017 Aug;181:75-82. doi: 10.1016/j.clim.2017.06.003. Epub 2017 Jun 15.PMID: 28625885 Free PMC article. Review.
Current Status of Dedicator of Cytokinesis-Associated Immunodeficiency: DOCK8 and DOCK2.
Dimitrova D, Freeman AF.Dermatol Clin. 2017 Jan;35(1):11-19. doi: 10.1016/j.det.2016.07.002.PMID: 27890234 Free PMC article. Review.